Hong Kong SAR

Pharmaron Beijing Co, a Chinese pharmaceutical research and development service platform, started testing investor appetite for its IPO on Monday.

Shanghai Fosun Pharmaceutical Group, which bought Indian company Gland Pharma in 2016, is planning to list the subsidiary on the National Stock Exchange of India and the BSE.

Hutchison Port Holdings Trust seized the market window immediately after the Federal Open Market Committee meeting to sell a $500m five year bond on Thursday.

Chinese biopharmaceutical firm 3SBio has taken one step closer to spinning off and listing a unit on Shanghai’s Nasdaq-style Star Market.

Goldman Sachs’ co-head of China investment banking Hansong Zhu is retiring after 19 years with the bank, according to an internal memo seen by GlobalCapital Asia.

Chinese pharmaceuticals firm WuXi Biologics and one of its controlling shareholders are set to raise a combined HK$7.9bn ($1bn) from the sale of equal chunks of shares in the company.

In this round-up, the Chinese Communist Party (CCP) said it will strengthen the country’s ideological and institutional design, the Chilean government called off a planned Apec meeting and the State Administration for Market Regulation (SAMR) and the People’s Bank of China released a list of certified fintech products.

In this round-up, China’s manufacturing Purchasing Managers’ Index fell below market expectation in October, Moody’s will acquire a minority stake in SynTao Green Finance and the People’s Bank of China will issue Rmb30bn ($4.3bn) of bills in Hong Kong next week.

It's no secret that tensions between North and South Korea are always simmering. But it is still a bit shocking to be confronted with the possibility that a potential disaster is right on your doorstep.

Morgan Stanley-backed China Feihe, a producer of infant milk formula, hit the road this week to drum up interest in its Hong Kong listing.

Agricultural Development Bank of China, one of three Chinese policy banks, bagged Rmb5.5bn ($781m) from a popular dual-tranche offshore renminbi bond on Wednesday, adding some life to the moribund dim sum market. Rebecca Feng reports.

SinoMab BioScience, a biopharmaceutical firm, has started taking orders for its up to HK$1.7bn ($223m) Hong Kong IPO.